The U.S. Food and Drug Administration recently marked 10 years since first updating the labeling for warfarin (often referred to as the "poster child" of pharmacogenomics) to include information regarding the potential impact of CYP2C9 and VKORC1 genetic variation on warfarin dosing requirements and risks. Herein, we opine on the experience updating the warfarin labeling, highlighting more generally the enabling factors and challenges encountered when considering incorporation of pharmacogenomic information into the prescribing recommendations for already approved drugs. We also provide a historical perspective of implemented changes in regulatory policies related to 
alleles. In addition, the Pharmacogenomics section We deliberated over 2 key issues that have become germane to the evaluation of most pharmacogenetic interactions identified in the post-marketing setting:
1) how prescriptive to be in terms of pharmacogenetic testing; and 2) the most useful way to convey the Drozda et al.
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